TRVI · Trevi Therapeutics, Inc.

Summary

Trevi Therapeutics, Inc. announced results of the Company’s End-of-Phase 2 meeting with the FDA on March 9, 2026. This disclosure under Item 8.01 represents a key regulatory milestone for the Company’s development program.

Key takeaways

• Trevi Therapeutics, Inc. announced End-of-Phase 2 meeting results on March 9, 2026.
• Meeting conducted with the FDA.
• Company incorporated in Delaware.